LCD Reference Article Response To Comments Article

Response to Comments: Treatment of Chronic Venous Insufficiency of the Lower Extremities

A58530

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
First Coast Service Options, Inc.	A and B MAC	09101 - MAC A	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09102 - MAC B	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09201 - MAC A	J - N	Puerto Rico Virgin Islands
First Coast Service Options, Inc.	A and B MAC	09202 - MAC B	J - N	Puerto Rico
First Coast Service Options, Inc.	A and B MAC	09302 - MAC B	J - N	Virgin Islands

Article Information

General Information

Article ID
A58530

Article Title
Response to Comments: Treatment of Chronic Venous Insufficiency of the Lower Extremities

Article Type
Response to Comments

Original Effective Date
11/12/2020

Retirement Date
N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

The following are the comment summaries and contractor responses for First Coast Service Options Proposed Local Coverage Determination (LCD) DL38720 Treatment of Chronic Venous Insufficiency of the Lower Extremities which was posted for comment on 6/25/2020, and presented at the July 2020 Open Meeting. All comments were reviewed and incorporated into the final LCD where applicable.

Response To Comments

Number	Comment	Response
1	A comment was received recommending some updates to the first paragraph of the "History/Background and/or General Information" section of the LCD to remove “Chronic Venous Insufficiency (CVI) from sentence 2 and include “and have reflux >500 milliseconds “ in sentence 3.	We appreciate your comments, after further consideration and review; the LCD is revised with the recommended changes. Thank you.
2	Multiple comments were received regarding the third paragraph of the "Terminology of veins discussed within this LCD" section of the LCD recommending to add verbiage for pathologic perforator veins, remove circumflex veins and include the terms Anterior Accessory Great Saphenous Vein (AAGSV)’ and “Posterior Accessory Great Saphenous Vein (PAGSV).	Thank you for the comments. Upon review, the LCD is revised with these recommendations.
3	Multiple comments were received recommending changes to the "Invasive Procedures for the management of chronic venous insufficiency" section of the LCD in regards to Foam Sclerosant: Ultrasound-Guided Foam Sclerotherapy (UGFS) to include the different types of foam: physician-compounded foam (PCF) and non-compounded foam (NCF) also referred to as (polidocanol endovenous microfoam - PEM). It was also recommended to correlate these changes to reflect in the “Covered Indications” section of the Proposed LCD and to differentiate the CPT codes in the related billing and coding article.	We would like to thank you for your comments. The LCD is revised to reflect the difference between the types of foam: physician-compounded foam (PCF) and non-compounded foam (NCF). The related billing and coding article was updated to differentiate the appropriate CPT codes (36465 & 36466 is used for NCF and 36470 & 36471 is used for PCF).
4	Multiple comments were received recommending some changes to the "Covered Indications" section of the LCD regarding duplex scan criteria; to reword the sentence that contains “spontaneous” and to remove the 1000 ms requirement.	We would like to thank you for your comments. After further review, the LCD is revised with the recommended verbiage to clarify the duplex scan covered indication.
5	Multiple comments were received recommending some changes to number 3 of the "Covered Indications" section of the LCD to clarify incompetent perforator vein management criteria for circumstances such as; An active venous ulcer is in close proximity to the IPV, OR The proximal significant reflux has been treated and an IPV persists under or adjacent to a healed venous ulcer, OR The proximal and regional venous reflux has been treated and there is persisting focal pain and tenderness or stasis dermatitis overlying an IPV, OR The incompetent perforator demonstrates reflux >500 ms and diameter > 3.5 mm.	We would like to thank you for your comments. After further review of the LCD, the incompetent perforator vein management covered indication is revised to reflect the following circumstances; An active venous ulcer is in close proximity to the IPV, OR The proximal significant reflux has been treated and an IPV persists under or adjacent to a healed venous ulcer, OR The proximal and regional venous reflux has been treated and there is persisting focal pain and tenderness or stasis dermatitis overlying an IPV, OR The incompetent perforator demonstrates reflux >500 ms and diameter > 3.5 mm.
6	Multiple comments were received recommending some changes to number 5 and 6 of the "Covered Indications" section of the LCD to remove “tributary veins” from thermal ablation and chemical adhesive treatment.	We appreciate your comments. The LCD is revised to remove “tributary veins” from thermal ablation and chemical adhesive treatment in the “Covered Indications” section of the LCD.
7	Multiple comments were received recommending revising the phlebectomy treatment covered indication. Suggestions received mention that treatment can be “after or at the same time as” treatment of the saphenous vein and to allow phlebectomy for any patient that has symptomatic bulbous varicosities greater than 3mm diameter regardless of their relationship to the saphenous vein.	We appreciate your comments. After further consideration and review, the LCD is revised to include that phlebectomy treatment may be staged or concomitant and the relationship to the saphenous vein was removed.
8	Multiple comments were received recommending some changes to the "Professional Societies” and “Consultation Summary" section of the LCD in reference to appropriately identifying the Societies attending the Consultation Summary meetings and to reword some of the verbiage to fully capture the content of the meetings.	Thank you for your comments. After further consideration and review, the LCD is revised to include the appropriate Societies and representatives for the Consultation Summary meetings. The LCD is also revised to include "chemical/cyanoacrylate adhesive" in the "Professional Societies: American College of Phlebology" and "Consultation Summary" sections of the LCD.
9	A commenter submitted a presentation and FDA article in regards to "Retrograde Administration of Ultrasound-Guided Microfoam Chemical Ablation vs Endovenous Laser Ablation for the Treatment of Superficial Venous Insufficiency."	The presentation and FDA article were reviewed and we would like to thank you for the submission of this information.
10	A comment was received to reconsider eliminating the conservative treatment period requirement in the "Conservative management for chronic venous insufficiency (Noninvasive procedures)" section of the Proposed LCD.	We appreciate your comments, after further review, the LCD is revised to include conservative treatment requirements in the covered indications section of the LCD and in the plan of care documentation requirements section of the billing and coding article.
11	A comment was received to clarify the purpose of Radiofrequency ablation in the "Invasive Procedures for the management of chronic venous insufficiency" section of the LCD.	Thank you for your comments. After further consideration and review, the LCD is revised to include the purpose of RFA is to damage the collagen of the vein wall resulting in fibrosis and occlusion of a vein segment to eliminate reflux.
12	A comment was received recommending revision to the "Invasive Procedures for the management of chronic venous insufficiency" section of the LCD for the chemical adhesive to clarify the purpose and process of this treatment.	Thank you for your comments. After further consideration and review, the LCD is revised with the recommendation and the section regarding chemical adhesive was updated accordingly.
13	Multiple comments were received recommending some changes to the "Invasive Procedures for the management of chronic venous insufficiency: Sclerotherapy: Liquid Sclerosant" and "Limitations" section of the LCD in regards to liquid sclerotherapy to remove the limitation and clarify that it can be used when addressing telangiectasia and their feeding reticular veins with spontaneous and/or traumatic venous hemorrhage or when unique patient features suggest liquid sclerotherapy may be the safer option.	Thank you for your comments. After further consideration and review, the LCD is revised to remove limitation number two for liquid sclerotherapy. The LCD is also revised to clarify that liquid sclerotherapy can be used when addressing telangiectasia and their feeding reticular veins with spontaneous and/or traumatic venous hemorrhage or when unique patient features suggest liquid sclerotherapy may be the safer option.
14	A comment was received to remove the statement "Agents must be used per the FDA approved label," from the "Covered Indications" section of the Proposed LCD due to product labeling being an issue between the FDA and the industry. Commenter also stated that it should not be a determinant in CMS coverage policy.	Thank you for your comments. After further consideration and review, the LCD is revised to remove the drug label and FDA approved indications statement and link.
15	A comment was received recommending some changes to the "Covered Indications" section of the LCD in regards to the fourth bullet under indication number 2. The commenter suggested adding limited coverage for C1 disease and language regarding conservative therapy.	We appreciate your comment. After further review, the LCD is revised with the recommended changes.
16	A comment was received to include provider qualifications within the proposed LCD for physicians who are board certified in vascular surgery, interventional radiology, or interventional cardiology.	Thank you for your comment. After further review, the LCD is not going to be revised to include any provider qualifications. It is the responsibility of the provider to comply with all applicable State and Federal laws related to the human use of agents.
17	A comment was received that recommended that no more than 3 ablations be approved for any one leg over the course of 1 year and a 90-day global period on a leg following an ablation.	Thank you for your comment. Medicare established a national definition of a global surgical package to ensure that Medicare Administrative Contractors (MACs) make payments for the same services consistently across all jurisdictions. At this time, the ablation procedure codes have not been assigned a global period. After further review, the LCD and the billing and coding article documentation requirements is revised to clarify that a plan of care is for a 90 day episode of care.
18	Multiple comments were received in support of the proposed LCD and related billing and coding article.	We would like to thank you for your comments.
19	Multiple comments received in regards to the title of the LCD and related billing and coding article to include “Surgical,” stating that the LCD addresses surgical treatments and not medical management.	We would like to thank you for your comment. After review of the LCD, the title of the LCD will not reflect a change to include “Surgical”. However, the LCD and billing and coding article is revised to clarify that the plan of care, covered indications and documentation requirements apply to invasive procedures.
20	A comment was received to add ICD-10 diagnosis codes in relation to the listed venous malformations or other complex malformations.	Thank you for your comment. After review of the Draft Local Coverage Article: Billing and Coding: Treatment of Chronic Venous Insufficiency of the Lower Extremities, the Local Coverage Article (LCA) is revised to include the following ICD-10-CM code; Q27.8, Other specified congenital malformations of peripheral vascular system.
21	A comment was received to include non-physician licensed independent providers (nurse practitioners and physician assistants) to those who are allowed to perform procedures covered within the LCD.	We appreciate your comment. Provider types and provider qualifications are not included within the LCD. It is the responsibility of the provider to comply with all applicable State and Federal laws related to the human use of agents.
22	A comment was received to exclude the requirement that a venous clinical severity score (VCSS) be recorded for every patient.	We appreciate your comment. After review of the LCD, the decision was made to not exclude the requirement for venous clinical severity score (VCSS) for each patient.
23	A comment was received that the LCD suggests that Medicare will cover ultrasound guided foam sclerotherapy for the first time. Will a new code be created for this procedure or will RVUs be assigned to S2202?	We appreciate your comment. Medicare and other federal payers do not recognize “S” codes; however, S codes may be useful for claims to some private insurers. For the purposes of this LCD/LCA, Physician-compounded foam (PCF) sclerotherapy is reported using CPT codes 36470 and 36471. Non-compounded foam (NCF) sclerotherapy is reported using CPT codes 36465 and 36466.

Coding Information

CPT/HCPCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description

Revenue Codes

Code	Description

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Related Local Coverage Documents
Articles
A58250 - Billing and Coding: Treatment of Chronic Venous Insufficiency of the Lower Extremities
LCDs
L38720 - Treatment of Chronic Venous Insufficiency of the Lower Extremities

Updated On	Effective Dates	Status
11/06/2020	11/12/2020 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

Please review and accept the agreements in order to view Medicare Coverage documents, which may include licensed information and codes.

LICENSE FOR USE OF PHYSICIANS' CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION ("CPT")

End User Point and Click Amendment:

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled "I Accept".

LICENSE FOR USE OF CURRENT DENTAL TERMINOLOGY (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org.
Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use. U.S. Government Rights Provisions.
Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.
ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement.

The ADA is a third party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: Treatment of Chronic Venous Insufficiency of the Lower Extremities

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Revenue Codes

CPT/HCPCS Codes

Group 1

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Revenue Codes

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: Treatment of Chronic Venous Insufficiency of the Lower Extremities (A58530)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS